Johan Dighed News Today

STOCKHOLM, SWEDEN – May 16, 2024. Karolinska Development AB (publ) (“Karolinska Development” or the “Company”) held the Annual General Meeting on May 16, 2024. The shareholders have had the right to exercise their voting rights in advance through postal voting pursuant to item 13 in the articles of association. Therefore, shareholders have had the choice to exercise their voting rights at the AGM by attending in person, by postal voting or through a proxy. The ...

STOCKHOLM, SWEDEN January 17, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has received...

STOCKHOLM, SWEDEN January 17, 2024. Karolinska Development AB today announces that its portfolio company AnaCardio has received the second tranche of SEK 50 million, completing the previously...

STOCKHOLM, SWEDEN, January 9, 2024. Karolinska Development AB announces that the portfolio company OssDsign reports positive data from the clinical study TOP FUSION. Top-line results show a 93%...

STOCKHOLM, SWEDEN, January 9, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that the portfolio company OssDsign reports positive data from the clinical study TOP FUSION. Top-line results show a 93% spinal fusion rate at 12 months as assessed with CT by independent radiological review after surgery with the novel nanosynthetic bone graft OssDsign Catalyst. The data, that has been submitted to a peer-reviewed scientific journal, indicates that the use of OssDsign Catalyst lead

STOCKHOLM, SWEDEN, December 6, 2023. Karolinska Development AB announces that the portfolio company OssDsign expects revenues for the fourth quarter of 2023 to exceed market expectations. Preliminary...

STOCKHOLM, SWEDEN November 8, 2023. Karolinska Development AB today announces that its portfolio company Modus Therapeutics has decided to carry out a rights issue that can raise up to approximately...

STOCKHOLM, SWEDEN November 8, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has...

STOCKHOLM, SWEDEN, October 2, 2023. Karolinska Development AB announces that its portfolio company PharmNovo has successfully completed its clinical phase 1 study with PN6047, a drug candidate...

STOCKHOLM, SWEDEN, September 28, 2023. Karolinska Development AB announces that its portfolio company PharmNovo has reported promising results in a preclinical study of the company’s drug candidate...